Epoprostenol Therapy for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved

Preventive Effect of Nutrition Support on Peroneal Neuropathy in Cancer Patients

Background: The occurrence of peroneal neuropathy was reported to be higher in cancer patients than in non-cancer patients. Cancer patients should have their nutritional intake carefully managed in order to minimize weight loss and avoid the occurrence of peroneal neuropathy. However, the effect of nutrition support on the prevention of peroneal neuropathy is not understood.Aims: The present study aimed to assess epidemiologically the effect of nutrition support on the occurrence of peroneal neuropathy in cancer patients.Methods: We performed a retrospective case-control study in 178,597 cancer patients admitted to Shizuoka Cancer Center Hospital from 2002 to 2017. The rates of peroneal neuropathy were assessed between the 8-year period before nutrition support started and the 7-year period during which nutrition support performed.Results: Twenty-nine and 14 cases of peroneal neuropathy occurred in the periods without and with nutrition support, respectively. Compared with the period without nutrition support, the risk of peroneal neuropathy decreased by 62% during the period with nutrition support (odds ratio, 0.38; 95% confidence interval, 0.18–0.74; P < 0.05).Conclusion: Our study suggests the preventive effects of nutrition support on peroneal neuropathy in cancer patients

Epoprostenol sodium for treatment of pulmonary arterial hypertension

　The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required

The East Asian Journal of British History, vol. 4

The East Asian Journal of British History is produced by the East Asian Society of British History, and supported by the Institute for Historical Research. The Institute of Historical Research is pleased and proud to be supporting this recent addition to British history scholarship. Developing out of the IHR’s long-standing collaborative partnership with Japanese universities, and now in its fourth year, the East Asian Journal of British History features some of the best emergent scholarship from Anglophone historians working in China, Japan, and South Korea. Divided between an articles section and one devoted to reviews, the journal’s remit wide-ranging covering all fields and periods of British history. It complements the triennial Anglo-Japanese Conference organised by the IHR and Japanese historians based at the universities of Tokyo, Kyoto and Osaka, and the conference of the East Asian Society of British history, in which we are joined by our colleagues from South Korea. In future, we hope that more contributions will be featured in the journal from the Chinese mainland and from Taiwan

Attitudes toward and current status of disclosure of secondary findings from next-generation sequencing: a nation-wide survey of clinical genetics professionals in Japan

The management of secondary findings (SFs), which are beyond the intended purpose of the analysis, from clinical comprehensive genomic analysis using next generation sequencing (NGS) presents challenges. Policy statements regarding their clinical management have been announced in Japan and other countries. In Japan, however, the current status of and attitudes of clinical genetics professionals toward reporting them are unclear. We conducted a questionnaire survey of clinical genetics professionals at two time points (2013 and 2019) to determine the enforcement of the SF management policy in cases of comprehensive genetic analysis of intractable diseases and clinical cancer genome profiling testing. According to the survey findings, 40% and 70% of the respondents stated in the 2013 and 2019 surveys, respectively, that they had an SF policy in the field of intractable diseases, indicating that SF policy awareness in Japan has changed significantly in recent years. Furthermore, a total of 80% of respondents stated that their facility had established a policy for clinical cancer genome profiling testing in the 2019 survey. In both surveys, the policies included the selection criteria for genes to be disclosed and the procedure to return SFs, followed by recommendations and proposals regarding SFs in Japan and other countries. To create a better list of the genes to be disclosed, further examination is needed considering the characteristics of each analysis

Seasonal level of hemoagglutinin inhibitinlt and its 2-mercaptoethanol sensitive antibody in the sera of swine (Epidemiological Study on Japanese Encephalitis, 67)

Seasonal level of hemoagglutinin inhibiting and its 2 -mercaptoethanol sensitive antibody in the sera of swine were researched and the following results were obtained. 1. The positive rate of hemoagglutination inhibit reaction (HI reaction) on swine showed 100% at maximum in the middle of September. 1980. The positive rate of 2-ME sensitive antibody showed the titer of over 1 : 40 with all swine examined in the middle of August, 1980. 2. The positive rate of HI reaction of inhabitants at Mukaiyama in Kurashiki City was 76.0% (on 8th in July, 1980) indicating the rather big decrease being compared with annual value of 90.6%, in 1976. Date indicated that increase In JE virus in swine as source of infection thought to be a vector of JE, caused a genuine case of JE, in 1980, as described below. 3. Higher positive rate of HI reaction and 2-ME sensitive positive rate of swine were observed in 1980. 4. One patient who suffered from JE was found In Kurashiki City in 1980. 5. Henceforth and continuously, Japanese Encephalitis should be investigated, above all on its occurance order with the number or Ct or the positive rate of hemoagglutination inhibit reaction in inhahitants and swine, etc. considering that J.E. has a high lethality rate and often leaves the terrible J. E. residue to patients